Disheng Pharma Grants AstraZeneca Global Rights to Cancer Drug Shuwozhe® for Up to $1.5 Billion
Disheng Pharmaceutical has announced a significant licensing agreement with AstraZeneca UK Limited, granting AstraZeneca exclusive global rights for the development and commercialization of its cancer drug, Shuwozhe® (daprodustat). This strategic partnership is expected to accelerate the drug's global reach and therapeutic application.
Under the terms of the agreement, Disheng Pharmaceutical will receive an upfront, non-refundable payment of $600 million from AstraZeneca. Additionally, the company is eligible for milestone payments totaling up to $400 million tied to clinical development achievements and a further $500 million contingent on sales performance. Beyond these milestone payments, Disheng Pharmaceutical will also receive tiered royalties on global net sales of Shuwozhe®, ranging from low double-digit percentages up to the highest tier. This transaction is classified as a related-party transaction but does not constitute a major asset restructuring. The deal is subject to review and approval by the company's shareholders.
This licensing agreement represents a substantial validation of Disheng Pharmaceutical's research and development capabilities, particularly in the oncology space. The substantial upfront payment and potential milestone earnings provide significant financial resources for Disheng to reinvest in its pipeline and operations. For AstraZeneca, acquiring global rights to Shuwozhe® offers a strategic expansion of its oncology portfolio, potentially leveraging its established global infrastructure to maximize the drug's market penetration. The tiered royalty structure incentivizes both parties: AstraZeneca to drive sales, and Disheng to see the drug succeed commercially. From a long-term perspective, this deal highlights the increasing trend of innovative biotech firms partnering with larger pharmaceutical giants to navigate the complex and capital-intensive global drug commercialization landscape, especially in the competitive field of cancer therapeutics.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.